Comparative Pharmacology
Head-to-head clinical analysis: THEOPHYL SR versus THEOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOPHYL SR versus THEOVENT.
THEOPHYL-SR vs THEOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular cAMP levels, and by antagonizing adenosine receptors.
300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/mL.
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
None Documented
None Documented
Adults: 8-10 hours (range 3-12); Neonates: 20-30 hours; Smokers: 4-5 hours; Cirrhosis: 30-40 hours. Dose adjustments needed based on half-life variations.
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Renal: ~10% unchanged; Hepatic metabolism (90%) via CYP1A2, 3A4; metabolites (caffeine, 3-methylxanthine) excreted renally. Total clearance predominantly hepatic.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator